ERT is designed to reduce the accumulation of glycosaminoglycans (GAGs) in the body, potentially slowing the progression of ocular symptoms like corneal clouding and retinal degeneration. However, while ERT addresses systemic symptoms, its direct impact on reversing or significantly improving ocular manifestations is still limited and may vary from patient to patient.